PV Bulletin
PvBulletin
Home /Devices/MHRA issues April 2026 Safety Roundup for medicines and devices
DevicesMhra

MHRA issues April 2026 Safety Roundup for medicines and devices

MHRA has published “MHRA Safety Roundup: April 2026” within the GOV.UK alerts/recalls stream. UK device vigilance teams should triage and document relevance.

PV Impact Brief

Urgency: MediumConfidence: medium
Relevant for
Local Safety OfficerSignal Management LeadRegulatory Intelligence LeadMedical Device Vigilance LeadPV Quality LeadQPPV
Processes impacted
Signal ValidationLocal Affiliate ComplianceDevice VigilanceRegulatory Intelligence MonitoringSignal Detection
Action needed

Mhra update requires triage for Signal Validation, Local Affiliate Compliance, Device Vigilance; confirm local obligations and document follow-up actions.

Owner

Local Safety Officer

Review cadence

Review in the next governance cycle and track weekly until closure.

Evidence and confidence

Confidence: mediumSource updated: Apr 29, 2026

Primary-source confirmation recommended before operational implementation.

Full briefing

What changed

MHRA has published “MHRA Safety Roundup: April 2026” within the GOV.UK alerts/recalls stream. UK device vigilance teams should triage and document relevance.

Why it matters

Potential impact spans Signal Validation, Local Affiliate Compliance, Device Vigilance, Regulatory Intelligence Monitoring, Signal Detection, so Local Safety Officer oversight is needed to maintain compliance readiness and evidence traceability.

Practical implication

Mhra update requires triage for Signal Validation, Local Affiliate Compliance, Device Vigilance; confirm local obligations and document follow-up actions.

#Medical Device Vigilance#Signal Management#Country Compliance#MHRA#Medical Devices#Regulatory Intelligence

Related updates for your role

RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUnited States

FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients

Regulatory action
Public Notification
Tawon Liar
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUnited States

Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)

Regulatory action
Recall
Shiley Cuffed Fenestrated Adult Tracheostomy Tube · Covidien (Medtronic)
Lot/batch: Z-2261-2026
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief →